Gilead Sciences Stock Price (NASDAQ:GILD)

Add to My Stocks
$69.94 $0.57 (0.82%) GILD stock closing price Feb 24, 2017 (Closing)
Gilead Sciences
24 FEB 2017
amigobulls logo
GILD hand_up
GILD vs S&P 500
Closing Price: Feb 24, 2017
$69.94 ( 0.82%)
S&P 500
2367.3 ( 0.15%)
52 Week Price Range
1 Year Return: -23.06%
Q4 Growth*
Profitable ?
net image
2016 Q4 Net Profit
Pays Dividend ?
12 Months Dividend
  : $1.76
Dividend Yield
  : 2.29%
PE Valuation
home image
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen

Gilead Sciences Snapshot Video

124 5 2

GILD Stock Details

Prev Close* : $69.37
Market Cap:
Day Low: $69.05
52 Week Low: $65.38
Open: $69.32
Volume: 7382357
Day High: $70.07
52 Week High: $103.10

Gilead Sciences, Inc. Business Profile

Gilead Sciences, Inc., is an American multinational corporation, headquartered in Foster City, California. Gilead Sciences, Inc. was founded in 1987, by Michael L. Riordan, a 29 year old medical doctor. The company is listed on Nasdaq and trades with the ticker symbol GILD. Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. he company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead stock has yielded phenomenal returns to its investors in the last five years as can be seen from href="" class="linkblue" title="Gilead historical stock prices">. The Gilead valuation shows the fundamental analysis of Gilead. It analyzes the revenue and profit growth over the past quarters to determine the financial health of the company. Gilead is a company which is continuously innovating. The company is mainly focused on developing the cure for Hepatitis C and HIV. The company shot into limelight after it developed the wonder drugs Haravoni and Sovaldi for treating Hepatitis C patients.

If one checks , one will see that Gilead stock price more than doubled after the launch of Harovini and Sovaldi.

More Information:


Gilead Investor Relations

Gilead Financial Information

more on GILD business profile

Gilead Sciences Stock Articles & Video

more news on GILD stock

Gilead Sciences News - From Partners

Five Major Myths about Options Trading   by Zacks on Feb 17, 2017

GILD Stockcharts

View GILD PE ratio, PS ratio stocks charts and compare with peers.
GILD Chart
Note: Compare Gilead Sciences stock price history with the index and industry peers.

Gilead Sciences Valuation

PE ratio
(price earnings ratio)
PS ratio (
price to sales ratio
PB ratio (
price to book ratio

Gilead Sciences Returns

(return on equity)

Gilead Sciences Financial Ratios

Asset Turnover
Receivables Turnover
Debt to Equity
Dividend Yield

GILD Industry Peers

Company Price Change (%)
Amgen (AMGN)174.560.55 (0.32%)
Celgene (CELG)118.231.23 (1.03%)
Pfizer (PFE)34.260.2 (0.59%)
Roche Holdings (RHHBY)30.60.06 (0.2%)
Glaxosmithkline (GSK)41.560.07 (0.17%)
Johnson & Johnson (JNJ)122.731.03 (0.85%)
Bristol-myers Squibb (BMY)56.440.67 (1.2%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
Incyte (INCY)131.219.26 (7.59%)
Sarepta Therapeutics (SRPT)32.021.87 (6.2%)
Stemline Therapeutics (STML)6.850.4 (6.2%)
Bluebird Bio (BLUE)823.7 (4.73%)
Puma Biotech (PBYI)36.21.5 (4.32%)
Sangamo BioSciences (SGMO)40.15 (3.9%)
Epizyme (EPZM)12.150.45 (3.85%)
Top gainers from Medical-Biomed-Genetics industry
* As of Feb 25, 2017
CompanyPriceChange (%)
Achillion Pharma (ACHN)3.860.38 (8.96%)
Chromadex (CDXC)2.740.13 (4.53%)
Idera Pharma (IDRA)1.670.06 (3.47%)
Inovio Pharma (INO)6.680.22 (3.19%)
VIVUS (VVUS)1.140.03 (2.56%)
Ligand Pharma (LGND)100.382.46 (2.39%)
Compugen (CGEN)4.30.1 (2.27%)
Top losers from Medical-Biomed-Genetics industry
* As of Feb 25, 2017

Gilead Sciences Financial Statements

income statement20152014201320122011
Net Sales Or Revenues32.64B24.89B11.2B9.7B8.39B
Net Income18.11B12.1B3.07B2.59B2.8B
Total Operating Expense6.44B5.84B3.82B3.22B2.47B
view Gilead Sciences, Inc. income statement
balance sheet20152014201320122011
Total Assets51.84B34.66B22.5B21.24B17.3B
Total Liabilities32.73B18.85B10.75B11.69B10.44B
Shareholders Equity19.11B15.82B11.74B9.55B6.87B
view Gilead Sciences, Inc. balance sheet
cash flow statement20152014201320122011
Net Increase (Decrease) In Assets Liabilities1.16B-518M-562.67M177.06M220.33M
Net Cash From (Used By) Operating Activities20.33B12.82B3.1B3.19B3.64B
Increase (Decrease) In Prop Plant And Equipment-747M-557M-190.78M-397.04M-131.9M
view Gilead Sciences, Inc. cashflow statement

Gilead Sciences, Inc. Stock News - Partner Headlines

Gilead Sciences Stock Message Board

An investor needs to spend 69.94 to buy GILD stock, as the closing Gilead Sciences stock price is 69.94. Gilead Sciences market capitalization is 90.87B and it represents the total market value of GILD stock. Gilead Sciences valuation can be guaged using various valuation metrics like the price to earnings ratio.

Demand for a stock decides its stock market price. For example, if more investors want to buy GILD stock than sell it, then Gilead Sciences stock price goes up. Conversely, if more investors wanted to sell GILD stock than buy it, there would be greater supply than demand, and the stock price would fall. 7382357 GILD shares were traded yesterday, and Gilead Sciences stock chart shows that the GILD stock quote hit a day high of 70.07 and day low of 69.05. Gilead Sciences paid 1.88 stock dividends to its shareholders during last quarter. One can observe stock price trends and check for volatility by checking Gilead Sciences stock price history.